Genetic markers and inflammatory bowel disease: immunoglobulin allotypes (GM, KM) and protease inhibitor.
We have studied immunoglobulin allotypes (GM and KM) in 101 patients with Crohn's disease, 51 patients with ulcerative colitis, and 99 healthy local blood donor controls. In addition, protease inhibitor (PI) types were examined in a random subset of patients and in all controls. No significant differences were found between Crohn's disease patients and controls, or between ulcerative colitis patients and controls, in the frequencies of GM phenotypes, GM haplotypes, KM phenotypes, or PI phenotypes.
Field
L L
LL
Department of Pediatrics, University of Calgary, Alberta, Canada.
Boyd
N
N
Bowen
T J
TJ
Kelly
J K
JK
Sutherland
L R
LR
D003093:Colitis, Ulcerative / Q000235:genetics*; D003424:Crohn Disease / Q000235:genetics*; D005819:Genetic Markers / Q000097:blood; D006801:Humans; D007126:Immunoglobulin Allotypes / Q000235:genetics*; D007129:Immunoglobulin Gm Allotypes / Q000235:genetics*; D010641:Phenotype; D011480:Protease Inhibitors / Q000235:genetics*
D005819:Genetic Markers; D007126:Immunoglobulin Allotypes; D007129:Immunoglobulin Gm Allotypes; D011480:Protease Inhibitors